# CureVac

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curevac

- Industry: Biotechnology
- Headquarters: Tubingen, Germany
- Website: www.curevac.com
- Total disclosed funding: $139M
- Latest round: Series D (Sep 17, 2012)
- Investors on record: 1

## About

CureVac AG, based in Germany, is a biotechnology company that develops innovative therapeutics using messenger RNA technology to combat various diseases, including cancer and infectious conditions.CureVac AG is a biotechnology firm specializing in mRNA-based therapeutics, founded in 2000 in Tubingen, Germany. The company has undergone strategic pivots and has raised a total of USD 250.00 mn across various funding rounds. The most recent funding, an Add-on Trade Sale, raised USD 1,250.00 mn on February 10, 2023, with investors including BioNTech SE. The firm is co-led by CEO Alexander Zehnder and CEO Franz-Werner Haas.CureVac specializes in developing innovative therapeutics based on messenger RNA (mRNA) technology. Its core products aim to create a new class of medicines targeting a range of diseases, including cancer and infectious diseases. By utilizing its proprietary RNA technology platform, the company enables the body to produce its own prophylactic and therapeutic proteins, enhancing the immune response. CureVac's products are primarily aimed at healthcare providers, pharmaceutical partners, and research institutions, with deployment in Europe, North America, and select Asian markets. The company has collaborated with major pharmaceutical companies to further expand its biopharmaceutical impact.In the year 2021, CureVac reported revenue of USD 121.84 mn, while experiencing an EBITDA loss of USD -469.16 mn. The company's revenue model heavily relies on strategic partnerships and collaborations, generating income through milestone payments, royalties on partnered product sales, and potential sales of therapeutics upon commercialization.CureVac AG aims to leverage its recent funding of USD 250.00 mn raised in February 2023 to support its expansion efforts and product development initiatives. The company plans to introduce new mRNA-based therapeutics in the coming years, targeting the market for cancer and infectious disease treatments. Additionally, CureVac is looking to expand its market presence in North America and Asia by 2024, aiming to establish new partnerships and enhance its distribution capabilities.

## Funding rounds

- Series D, Sep 17, 2012, $102M — Dievini
- Series C, May 10, 2010, $36M — Dievini

## Investors

- Dievini (https://capitalatlas.ai/funds/dievini) — Series C, Series D